Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest update is out from NeOnc Technologies Holdings, Inc. ( (NTHI) ).
On August 18, 2025, NeOnc Technologies Holdings, Inc. completed the acquisition of JandB Holdings, LLC, making it a wholly owned subsidiary. Concurrently, Dr. Ming-Fu Chiang resigned from the Board, and Ishwar Puri was elected as a new director. NeOnc also reported its second quarter 2025 results, highlighting a $50 million strategic partnership with Quazar Investment, NIH funding for gliomas and leukemia research, and the acquisition of AI and quantum modeling IP. The company aims to expand its clinical trials platform in the GCC & MENA regions and enhance its market presence through media campaigns and index inclusion.
More about NeOnc Technologies Holdings, Inc.
NeOnc Technologies Holdings, Inc. is a multi–Phase 2 clinical-stage biotechnology company focused on developing novel therapies for brain cancer and other central nervous system disorders. The company is known for its robust intellectual property portfolio, advanced delivery platforms, and collaborations with leading academic centers.
Average Trading Volume: 203,265
Technical Sentiment Signal: Strong Sell
Find detailed analytics on NTHI stock on TipRanks’ Stock Analysis page.